Regeneron - activities

Covid: Kevzara (sarilumab) underperforming as a therapy, according to an AP-HP study

According to an AP-HP study issued this November 23, 2021, Kevzara (sarilumab) - a potential cure to Covid - does not seem to have delivered conclusive results as for its effectiveness to avoid deaths after hospitalization. The study confirms results of the clinical trial led by Sanofi who announced in September 2020 they were ending their clinical trial after results of this study were inconclusive.

Covid: antibody cocktail Regeneron working up to eight months, the laboratory claims

Good news in the search for the fight against Covid… Regeneron announced their antibody cocktail injected in cases of severe disease was 80% effective for at least eight months, according to the drugmaker’s latest studies. It involves a cocktail of antibodies given in 2020 to U.S. President Trump when we was hospitalized for severe covid.

Covid: effectiveness of monoclonal antibodies challenged by variants

As Covid variants keep on spreading across the world, Eli Lilly laboratories has seen their approval removed for marketing bamlanivimab, as a monotherapy, being a therapy based on monoclonal antibodies. Why? Its effectiveness challenged by new coronavirus strains. Keep reading to find out more!

Covid: casirivimab/imdevimab cocktail, Regeneron’s promising treatment against the virus

This Monday April 12, Roche and Regeneron laboratories have issued results from phase 3 of their clinical trial for a treatment against Covid, a cocktail of casirivimab and imdevimab able to cut the risk of transmitting the virus within populations.

Covid: France has approved two monoclonal antibody therapies

This Monday March 15, the Agence du Médicament (French Medicines Agency) announced that two monoclonal antibody therapies, namely REGN-COV2 and Eli Lilly laboratory's therapy based on bamlanivimab and etesevimab were now approved in France.